Adamax

What it is

Adamax is a grey-market nootropic peptide name that appears in public peptide commerce and in regulatory monitoring material, but it does not currently have the peer-reviewed footprint expected of a well-characterized investigational drug. The strongest official source identified for this draft is a June 2025 Medsafe submission to New Zealand’s Medicines Classification Committee, which lists Adamax and Semax as examples of ACTH analogues marketed as cognitive enhancers^{[6 ]}.

The name is generally used online for a Semax-related compound. Semax itself is a synthetic heptapeptide ACTH analogue with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, also abbreviated MEHFPGP^{[7 ]}. Semax has a published Russian and preclinical literature, including studies in cerebral ischemia, optic nerve disease, and other neurologic contexts^{[8 –11 ]}. Adamax should not be assumed to share Semax’s pharmacology, safety profile, or evidence base unless Adamax-specific data demonstrate that.

Public descriptions often say Adamax combines Semax-like ACTH-fragment structure with an adamantane-based modification intended to increase stability or brain penetration. Adamantane modification is a real chemical strategy in some peptide-mimetic research, including the P021 literature^{[12 ]}. However, the existence of adamantane-containing P021 studies does not validate Adamax claims. This page therefore separates Semax context, P021 chemical-design context, and Adamax-specific evidence.

Medsafe’s June 2025 document provides a useful regulatory lens. It describes a broader rise in unscheduled peptides imported for personal use, often sold “for research purposes only” while being purchased by individuals intending therapeutic administration^{[6 ]}. It also states that ACTH analogues tend to make nootropic claims through neurogenesis and brain-derived neurotrophic factor narratives, while their mechanism of action is often unknown and clinical research and long-term safety information are limited^{[6 ]}.

No clinical administration route can be described for Adamax to publication standard. Online sellers and forums may discuss intranasal or injectable use, but those sources are not clinical evidence and are not included as guidance. This page should be treated as an evidence-insufficient regulatory and research-status entry unless verifiable primary chemistry and pharmacology sources are supplied.

This makes Adamax different from peptides with sparse but real indexed animal literature. The editorial issue is not merely that the evidence is weak; it is that the identity-to-outcome chain could not be independently verified from primary sources.

Regulatory status

Adamax is not FDA-approved for cognitive enhancement, focus, neuroprotection, traumatic brain injury, stroke recovery, depression, attention symptoms, neurogenesis, BDNF modulation, or any other indication in the United States. No FDA-approved drug label or prescribing information for Adamax was identified in the sources reviewed for this draft^{[1 –5 ]}.

503A category list

Adamax was not identified by name on FDA’s April 22, 2026 503A category list of nominated bulk drug substances^{[2 ]}. Semax, a related ACTH analogue and the parent compound most often invoked in Adamax marketing, has a separate FDA compounding history: FDA’s April 2026 materials state that Semax was removed from 503A Category 2 because nominations were withdrawn, and FDA scheduled Semax-related free-base and acetate substances for PCAC discussion on July 24, 2026^{[2 –3 ]}. Those Semax actions do not authorize Adamax compounding.

General compounding framework

FDA’s general compounding framework remains the key rule set. For 503A compounding, state-licensed physicians and pharmacists using bulk drug substances must meet statutory conditions, including using substances with applicable USP/NF monographs, components of FDA-approved drugs when no monograph exists, or substances on FDA’s 503A bulks list^{[1 ]}. For 503B outsourcing facilities, FDA states that bulk substances generally must either appear on the 503B bulks list or be used in a compounded drug that appears on the shortage list at the relevant time^{[1 ]}.

Semax safety-risk page (analogue-only context)

FDA’s safety-risk page for nominated bulk substances is relevant by analogy only. It says compounded drugs containing Semax may pose immunogenicity risk for certain routes because of aggregation and peptide-related impurities, and that FDA has no or limited safety-related information for proposed routes^{[4 ]}. That FDA statement is about Semax, not Adamax. It should not be quoted as an Adamax-specific risk determination, but it does underscore why modified peptide analogues require route-specific safety data.

Adamax was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[5 ]}. That does not imply FDA approval, lawful marketing, compounding eligibility, safety, or quality.

International — New Zealand Medsafe

Internationally, New Zealand regulatory authorities have considered Adamax within a proposed ACTH-analogue group entry. Medsafe recommended that ACTH analogues, including Adamax and Semax, be classified as prescription medicines in New Zealand^{[6 ]}. This is a regulatory classification proposal, not an efficacy finding.

Date of last regulatory verification: May 7, 2026.

Research summary

No Adamax-specific peer-reviewed clinical trials, pharmacokinetic studies, toxicology studies, receptor-binding studies, or animal efficacy studies were identified for this draft. That absence is the central finding. A publication-ready Adamax page should not extrapolate from Semax, P021, or general nootropic peptide discourse as if those sources were Adamax studies.

Semax context — not Adamax evidence

The closest related literature is Semax. PubChem identifies Semax as MEHFPGP, a heptapeptide ACTH analogue^{[7 ]}. Bashkatova and colleagues reported that Semax, but not glycine, prevented enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia^{[8 ]}. Sudarkina and colleagues reported brain protein-expression findings consistent with a protective effect of ACTH(4-7)PGP, Semax, in a rat cerebral ischemia-reperfusion model^{[9 ]}. These studies support biological activity for Semax in specific preclinical models, not Adamax.

Human Semax literature is mostly older and geographically concentrated. Polunin and colleagues evaluated Semax in optic nerve disease and partial optic nerve atrophy in a Russian ophthalmology publication^{[10 ]}. Alekseeva and colleagues studied Semax in follow-up of patients with posthypoxic encephalopathy and reported EEG episodes of paroxysmal activity after Semax injection in some cases^{[11 ]}. These reports are relevant background for Semax but cannot establish Adamax efficacy or safety.

P021 chemistry context — not Adamax evidence

The Adamax marketing rationale often invokes chemical modification to improve stability or blood-brain-barrier penetration. P021 provides an example of adamantane-containing peptide-mimetic research: Li and colleagues described adamantane-containing neurotrophic peptides, including P21/P021, that improved learning and memory and promoted neurogenesis and synaptic plasticity in mice^{[12 ]}. Again, this is chemical-design context, not Adamax evidence.

Medsafe regulatory framing

Medsafe’s regulatory summary is more consistent with an evidence-insufficient interpretation than with therapeutic validation. It states that ACTH analogues tend to make nootropic claims through neurogenesis and BDNF narratives, that their mechanism of action is often unknown, and that little is known about side effects or long-term effects^{[6 ]}. That assessment aligns with this review’s inability to identify direct Adamax studies.

The strongest defensible editorial statement is narrow: Adamax is a marketed research peptide name associated with ACTH/Semax-analogue claims, but no Adamax-specific peer-reviewed evidence was found to substantiate claims about cognition, BDNF, neurogenesis, neuroprotection, focus, mood, stroke recovery, or brain repair. If future sources identify a verified Adamax structure and controlled pharmacology studies, this page should be revised from the ground up rather than patched with extrapolations.

Public discourse

No qualifying named physician, researcher, podcast host, or public figure with a verifiable primary quote was identified for Adamax during this review.

Adamax does appear in vendor pages, peptide databases, anonymous forum posts, and social media discussions. Those sources commonly describe it as a stronger or longer-lasting Semax variant and make claims about BDNF, focus, neuroplasticity, or brain penetration. These claims were not included as factual support because they were not tied to Adamax-specific peer-reviewed studies, FDA-reviewed documents, or named expert commentary with primary-source verification.

Medsafe’s June 2025 classification submission is the most credible public document located, but it is a regulatory submission rather than a named public commentary source. It is cited in the Regulatory Status and Research Summary sections because it addresses importation, claimed use, and uncertainty around ACTH analogue peptides^{[6 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Adamax has no FDA-approved prescribing information. There is no FDA-reviewed adverse-reaction table, contraindication list, human pharmacokinetic profile, drug-interaction section, pregnancy or lactation guidance, route-specific safety assessment, abuse-potential assessment, or postmarketing surveillance dataset^{[1 –5 ]}.

Uncertainty is the central safety issue

The most important safety issue is uncertainty. Without peer-reviewed Adamax-specific identity, purity, pharmacology, route, and human-exposure data, there is no reliable way to quantify adverse-event rates or define risk factors. Claims that a modified peptide is “more stable” or “more brain-penetrant” do not establish that it is safer.

Related-compound context

Related-compound context should be handled carefully. FDA’s safety-risk page for Semax notes possible immunogenicity concerns for certain routes because of aggregation and peptide-related impurities and limited route-specific safety information^{[4 ]}. Medsafe similarly states that little is known about side effects or long-term effects for ACTH analogues^{[6 ]}. These sources do not prove Adamax has the same risks, but they support a conservative stance toward unapproved modified peptide analogues.

Product-quality concerns

Potential concerns include peptide aggregation, immunogenicity, inaccurate sequence, chemical impurities, incorrect salt or counterion, microbial contamination, endotoxin contamination, solvent residues, poor storage stability, and concentration errors. Intranasal and injectable routes raise additional formulation and sterility questions.

Neuropsychiatric concerns

Neuropsychiatric and neurologic concerns are also plausible because the marketed rationale centers on cognitive and neurotrophic effects. People with seizure disorders, migraine, psychiatric conditions, traumatic brain injury, stroke history, pregnancy, pediatric use, or use of neurologic medications would require clinical safety evidence that currently does not exist for Adamax.

Long-term safety data are absent. Adamax should be described as an evidence-insufficient grey-market research peptide, not a clinically validated nootropic or neuroprotective therapy.

Available through

Adamax is not currently available through FDA-compliant channels in the United States as of 2026-05-07. ProPeptideGuide does not link to or endorse grey-market vendors.